Quarterly report · Q2

Period2022-04-01 → 2022-09-30
Filed2022-11-08
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 59
MetricValuePeriodScopeSource row
Revenue¥1.53T2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥754.4bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥2.77T2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥1.33T2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥686.2bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥60.6bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income−¥5.7bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥144.3bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥85.9bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥126.8bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥13.1bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥251.1bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥146.8bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥90.1bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥81.1bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥11.1bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥162.1bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥88.9bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥53.2bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥73.1bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income−¥12.0bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥186.4bn2021-04-01 → 2022-03-31Cons.Profit loss IFRS (5-year summary)
Net income¥107.8bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥68.9bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥4.68Tat 2022-09-30Cons.Assets IFRS
Total assets¥4.31Tat 2022-03-31Cons.Assets IFRS
Total assets¥4.08Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.79Tat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥2.61Tat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.89Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.70Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥1.55Tat 2021-09-30Cons.Equity IFRS
Net assets / equity¥1.48Tat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.38Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.22Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.08Tat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥486.0bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥365.4bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥346.8bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥360.9bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥83.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥171.7bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥77.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow¥15.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥115.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥65.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥24.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥81.4bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥27.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥49.582022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥6.772022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥99.162021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥54.362021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥32.552021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥49.572022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥6.772022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio29.5%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.3%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio26.5%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 124
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥79.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-07-01 → 2022-09-30¥47.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥37.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-07-01 → 2022-09-30¥23.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥42.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-07-01 → 2022-09-30¥24.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30¥2.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-07-01 → 2022-09-30−¥708m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥57.6bn
Reconciling Itemsreconcilingrevenue2022-07-01 → 2022-09-30−¥32.7bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥57.6bn
Reconciling Itemsreconcilingrevenue intersegment2022-07-01 → 2022-09-30−¥32.7bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥11.6bn
Reconciling Itemsreconcilingsegment profit2022-07-01 → 2022-09-30−¥4.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-04-01 → 2022-09-30¥183.7bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-07-01 → 2022-09-30¥92.4bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-04-01 → 2022-09-30¥173.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-07-01 → 2022-09-30¥87.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥10.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥5.3bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-04-01 → 2022-09-30¥13.4bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-07-01 → 2022-09-30¥6.8bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-04-01 → 2022-09-30¥470.4bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-07-01 → 2022-09-30¥230.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-04-01 → 2022-09-30¥467.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-07-01 → 2022-09-30¥228.7bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥3.1bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥1.6bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-04-01 → 2022-09-30¥23.3bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-07-01 → 2022-09-30¥13.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-04-01 → 2022-09-30¥295.9bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-07-01 → 2022-09-30¥142.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-04-01 → 2022-09-30¥293.9bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-07-01 → 2022-09-30¥141.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥2.0bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥1.1bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-04-01 → 2022-09-30¥36.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-07-01 → 2022-09-30¥14.4bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-04-01 → 2022-09-30¥222.4bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-07-01 → 2022-09-30¥107.7bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-04-01 → 2022-09-30¥222.2bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-07-01 → 2022-09-30¥107.5bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥234m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥118m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-04-01 → 2022-09-30¥26.4bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-07-01 → 2022-09-30¥10.7bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2022-04-01 → 2022-09-30¥334.5bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2022-07-01 → 2022-09-30¥166.7bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2022-04-01 → 2022-09-30¥334.4bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2022-07-01 → 2022-09-30¥166.7bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥7m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-07-01 → 2022-09-30¥1m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2022-04-01 → 2022-09-30¥25.2bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2022-07-01 → 2022-09-30¥11.1bn
—segment totalrevenue2022-04-01 → 2022-09-30¥1.51T
—segment totalrevenue2022-07-01 → 2022-09-30¥739.5bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥1.49T
—segment totalrevenue external2022-07-01 → 2022-09-30¥731.4bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥15.5bn
—segment totalrevenue intersegment2022-07-01 → 2022-09-30¥8.1bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥124.7bn
—segment totalsegment profit2022-07-01 → 2022-09-30¥56.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-04-01 → 2021-09-30¥59.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2021-07-01 → 2021-09-30¥31.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-04-01 → 2021-09-30¥30.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2021-07-01 → 2021-09-30¥17.0bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-04-01 → 2021-09-30¥29.1bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2021-07-01 → 2021-09-30¥14.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-04-01 → 2021-09-30¥6.8bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2021-07-01 → 2021-09-30¥4.0bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-09-30−¥41.3bn
Reconciling Itemsreconcilingrevenue2021-07-01 → 2021-09-30−¥20.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-09-30−¥41.3bn
Reconciling Itemsreconcilingrevenue intersegment2021-07-01 → 2021-09-30−¥20.3bn
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥10.4bn
Reconciling Itemsreconcilingsegment profit2021-07-01 → 2021-09-30−¥5.4bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2021-04-01 → 2021-09-30¥154.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue2021-07-01 → 2021-09-30¥77.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2021-04-01 → 2021-09-30¥148.5bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2021-07-01 → 2021-09-30¥74.1bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥6.0bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥3.0bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2021-04-01 → 2021-09-30¥12.6bn
jpcrp040300-q2r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2021-07-01 → 2021-09-30¥5.9bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2021-04-01 → 2021-09-30¥402.1bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2021-07-01 → 2021-09-30¥201.4bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2021-04-01 → 2021-09-30¥399.5bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2021-07-01 → 2021-09-30¥200.0bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥2.6bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥1.4bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2021-04-01 → 2021-09-30¥42.0bn
jpcrp040300-q2r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2021-07-01 → 2021-09-30¥18.2bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2021-04-01 → 2021-09-30¥212.8bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2021-07-01 → 2021-09-30¥107.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2021-04-01 → 2021-09-30¥209.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2021-07-01 → 2021-09-30¥106.4bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥3.3bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥955m
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2021-04-01 → 2021-09-30¥18.5bn
jpcrp040300-q2r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2021-07-01 → 2021-09-30¥8.2bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2021-04-01 → 2021-09-30¥227.9bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue2021-07-01 → 2021-09-30¥118.5bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2021-04-01 → 2021-09-30¥227.7bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2021-07-01 → 2021-09-30¥118.4bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥226m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥116m
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2021-04-01 → 2021-09-30¥29.5bn
jpcrp040300-q2r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2021-07-01 → 2021-09-30¥16.0bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2021-04-01 → 2021-09-30¥309.6bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue2021-07-01 → 2021-09-30¥170.4bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2021-04-01 → 2021-09-30¥309.6bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue external2021-07-01 → 2021-09-30¥170.4bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-09-30¥9m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentrevenue intersegment2021-07-01 → 2021-09-30¥7m
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2021-04-01 → 2021-09-30¥50.0bn
jpcrp040300-q2r_E00752-000Medical Productsreportable segmentsegment profit2021-07-01 → 2021-09-30¥40.3bn
—segment totalrevenue2021-04-01 → 2021-09-30¥1.31T
—segment totalrevenue2021-07-01 → 2021-09-30¥674.7bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥1.29T
—segment totalrevenue external2021-07-01 → 2021-09-30¥669.2bn
—segment totalrevenue intersegment2021-04-01 → 2021-09-30¥12.2bn
—segment totalrevenue intersegment2021-07-01 → 2021-09-30¥5.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥152.6bn
—segment totalsegment profit2021-07-01 → 2021-09-30¥88.6bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 994
ItemContextValueUnit
Proceeds from long term borrowings fin cf IFRSPrior1YTDDuration33659000000JPY
Proceeds from long term borrowings fin cf IFRSCurrentYTDDuration15194000000JPY
Repayments of long term borrowings fin cf IFRSPrior1YTDDuration-70055000000JPY
Repayments of long term borrowings fin cf IFRSCurrentYTDDuration-106323000000JPY
Redemption of bonds fin cf IFRSPrior1YTDDuration-14287000000JPY
Redemption of bonds fin cf IFRSCurrentYTDDuration-JPY
Repayments of lease obligations fin cf IFRSPrior1YTDDuration-7848000000JPY
Repayments of lease obligations fin cf IFRSCurrentYTDDuration-8784000000JPY
Dividends paid fin cf IFRSPrior1YTDDuration-14715000000JPY
Dividends paid fin cf IFRSCurrentYTDDuration-22862000000JPY
Dividends paid to non controlling interests fin cf IFRSPrior1YTDDuration-5585000000JPY
Dividends paid to non controlling interests fin cf IFRSCurrentYTDDuration-10085000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSPrior1YTDDuration-3916000000JPY
Payments for acquisition of interests in subsidiaries from non controlling interests fin cf IFRSCurrentYTDDuration-JPY
Other fin cf IFRSPrior1YTDDuration1138000000JPY
Other fin cf IFRSCurrentYTDDuration28000000JPY
Net cash provided by used in financing activities IFRSPrior1YTDDuration-27148000000JPY
Net cash provided by used in financing activities IFRSCurrentYTDDuration-24658000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSPrior1YTDDuration987000000JPY
Effect of exchange rate changes on cash and cash equivalents IFRSCurrentYTDDuration46153000000JPY
Net increase decrease in cash and cash equivalents IFRSPrior1YTDDuration-14113000000JPY
Net increase decrease in cash and cash equivalents IFRSCurrentYTDDuration120567000000JPY
Cash and cash equivalents IFRSPrior2YearInstant360918000000JPY
Cash and cash equivalents IFRSPrior1YearInstant365429000000JPY
Cash and cash equivalents IFRSPrior1QuarterInstant346805000000JPY
Cash and cash equivalents IFRSCurrentQuarterInstant485996000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember399485000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember148477000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember227656000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember209427000000JPY
Revenue from external customers IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember309580000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReportableSegmentsMember1294625000000JPY
Revenue from external customers IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember30585000000JPY
Revenue from external customers IFRSPrior1YTDDuration_ReconcilingItemsMember-JPY
Revenue from external customers IFRSPrior1YTDDuration1325210000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember2639000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember6017000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember226000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember3329000000JPY
Intersegment revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember9000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReportableSegmentsMember12220000000JPY
Intersegment revenue IFRSPrior1YTDDuration_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember29051000000JPY
Intersegment revenue IFRSPrior1YTDDuration_ReconcilingItemsMember-41271000000JPY
Intersegment revenue IFRSPrior1YTDDuration-JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000EssentialChemicalsAndPlasticsReportableSegmentMember402124000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000EnergyAndFunctionalMaterialsReportableSegmentMember154494000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000InformationElectronicChemistryReportableSegmentMember227882000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000HealthAndAgricultureRelatedReportableSegmentMember212756000000JPY
Revenue IFRSPrior1YTDDuration_jpcrp040300-q2r_E00752-000MedicalProductsReportableSegmentMember309589000000JPY
Revenue IFRSPrior1YTDDuration_ReportableSegmentsMember1306845000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass